Overview
- The FDA approved atacicept‑vymj (Trutakna) to reduce proteinuria in adults with primary IgA nephropathy, with the decision announced Tuesday and issued under the agency’s accelerated approval rules.
- Trutakna is the first approved drug to target both B‑cell activating factor (BAFF) and APRIL, two immune signals linked to the abnormal IgA antibodies that damage the kidney’s filtering units.
- Approval relied on a prespecified interim analysis from the phase III ORIGIN 3 trial that showed roughly a 45% proteinuria decline with atacicept versus about 7% with placebo and large drops in disease biomarkers.
- The label warns of immunosuppression and higher infection rates seen in ORIGIN 3 (about one third of patients) and lists injection‑site reactions as a common side effect; full approval requires confirmatory two‑year eGFR data.
- The drug is a once‑weekly self‑injected therapy that joins several recently approved options for IgA nephropathy and could change care choices for patients and clinicians while commercial launch and Q3 eGFR readouts unfold.